IRAPs (Secreted Insulin Regulated AminoPeptidase): a New Insulin Sensitivity Biomarker

Civil Hospices of Lyon

Status: Completed

Conditions: Insulin Resistance

Treatments: Other: It is a hyperinsulinemic-euglycemic clamp.

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01648478

2011.705

Details and patient eligibility

About

Previous studies have demonstrated defects in the trafficking and translocation of GLUT4 glucose transporter in skeletal muscle and adipose tissue to be a major cause of insulin resistance in humans. IRAP (Secreted Insulin Regulated AminoPeptidase) is a protein which collocalizes and is translocated with GLUT4 to the plasma membrane in response to insulin. The extracellular domain of IRAP is cleaved and released in the bloodstream.

Therefore, IRAP plasma concentration could be a good marker of insulin sensitivity.

In this study the investigators seek to confirm this hypothesis by using the gold standard of insulin sensitivity assessment: the hyperinsulinemic-euglycemic clamp.

It is a multicenter descriptive study.

Enrollment: 21 patients

Sex: All

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Men and women (sex ratio = 1)
• Aged from 18 to 35 years
• Fasting glycemia < 6mmol/L
• Total cholesterol < 7mmol/L
• Triglycerides < 1.5 mmol/L
• CRPus < 5 mg/L
• Creatinine clearance < 80mL/min according to Cockroft formula
• Liver enzymes (ALanine AminoTransférase and ASpartate AminoTransférase) < 1.5 times normal values

Exclusion criteria

• Subject not in compliance with the recommendations of French National Law in force
• Medical history of metabolic disease (diabetes, dyslipidemia), endocrine disease, renal insufficiency
• Drug use that could affect glucose metabolism and the renin angiotensin aldosterone system
• Blood pressure > 140/90mmHg
• Tea and coffee consumption more than 5 cups per day
• Subject who smoke more than 5 cigarettes per day

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

21 participants in 1 patient group

Single Arm

Experimental group

Treatment:

Other: It is a hyperinsulinemic-euglycemic clamp.